CPI-613, Catalog: 9464

Alternate Name 6,8-Bis[(phenylmethyl)thio]octanoic acid

Appearance White solid

CAS # 95809-78-2

Molecular Formula C₂₂H₂₈O₂S₂

Molecular Weight 388.59

Purity ≥ 98% by HPLC

Solubility DMSO (>30 mg/ml) or EtOH (>20 mg/ml)

SMILES C1=CC=C(C=C1)CSCCC(CCCCC(=O)O)SCC2=CC=CC=C2

InChi InChI=1S/C22H28O2S2/c23-22(24)14-8-7-13-21(26-18-20-11-5-2-6-12-20)15-16-25-17-19-9-3-1-4-10-19/h1-6,9-12,21H,7-8,13-18H2,(H,23,24)

InChi Key ZYRLHJIMTROTBO-UHFFFAOYSA-N

PubChem CID 24770514

MDL Number MFCD22420826

Storage Conditions -20°C

Shipping Conditions Gel Pack

USAGE For Research Use Only! Not For Use in Humans.

Handling Do not take it internally. Wear a glove and mask when handling the product. Protect from air, light and moisture.

CPI-613 is a non-redox active lipoate derivative that acts as a selective inhibitor mitochondrial enzymes pyruvate dehydrogenase (PDH) and α-ketoglutarate dehydrogenase. In vitro, CPI-613 dose-dependently and efficiently kills H460 human lung cancer cells and Saos-2 human sarcoma cells. In vitro, CPI-613 treatment potently disrupts H460 cancer cell mitochondrial metabolism including inhibition of PDH complex activity. CPI-613 treatment also leads to loss of mitochondrial membrane potential as assessed by JC-1 mitochondrial uptake. CPI-613 also induces apoptotic and non-apoptotic cell death in the cells of H460 human lung cancer and Saos-2 human sarcoma in vitro.